Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication

Página do item simplificado
dc.citation.volume8]
dc.contributor.authorAghamohammadi, Asghar
dc.contributor.authorAbolhassani, Hassan
dc.contributor.authorKutukculer, Necil
dc.contributor.authorWassilak, Steve G.
dc.contributor.authorPallansch, Mark A.
dc.contributor.authorKluglein, Samantha
dc.contributor.authorQuinn, Jessica
dc.contributor.authorSutter, Roland W.
dc.contributor.authorWang, Xiaochuan
dc.contributor.authorSanal, Ozden
dc.contributor.authorLatysheva, Tatiana
dc.contributor.authorIkinciogullari, Aydan
dc.contributor.authorBernatowska, Ewa
dc.contributor.authorTuzankina, Irina A.
dc.contributor.authorCosta-Carvalho, Beatriz T. [UNIFESP]
dc.contributor.authorLuis Franco, Jose
dc.contributor.authorSomech, Raz
dc.contributor.authorKarakoc-Aydiner, Elif
dc.contributor.authorSingh, Surjit
dc.contributor.authorBezrodnik, Liliana
dc.contributor.authorEspinosa-Rosales, Francisco J.
dc.contributor.authorShcherbina, Anna
dc.contributor.authorLau, Yu-Lung
dc.contributor.authorNonoyama, Shigeaki
dc.contributor.authorModell, Fred
dc.contributor.authorModell, Vicki
dc.contributor.authorBarbouche, Mohamed-Ridha
dc.contributor.authorMcKinlay, Mark A.
dc.coverageLausanne
dc.date.accessioned2020-06-26T16:30:37Z
dc.date.available2020-06-26T16:30:37Z
dc.date.issued2017
dc.description.abstractImmunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or yearsen
dc.description.abstractthe excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.en
dc.description.affiliationUniv Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Tehran, Iran
dc.description.affiliationEge Univ, Dept Pediat Immunol, Fac Med, Izmir, Turkey
dc.description.affiliationCtr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA
dc.description.affiliationCtr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA
dc.description.affiliationCtr Vaccine Equ, Task Force Global Hlth, Atlanta, GA USA
dc.description.affiliationJeffrey Modell Fdn, New York, NY USA
dc.description.affiliationWHO, Res & Product Dev, Geneva, Switzerland
dc.description.affiliationFudan Univ, Childrens Hosp, Dept Clin Immunol, Shanghai, Peoples R China
dc.description.affiliationHacettepe Univ, Fac Med, Dept Pediat, Div Immunol, Ankara, Turkey
dc.description.affiliationInst Immunol, Dept Allergol & Immunotherapy, Moscow, Russia
dc.description.affiliationAnkara Univ, Sch Med, Dept Pediat Immunol & Allergy, Ankara, Turkey
dc.description.affiliationChildrens Mem Hlth Inst, Dept Clin Immunol, Warsaw, Poland
dc.description.affiliationRussian Acad Sci, Ural Branch, Inst Immunol & Physiol, Ekaterinburg, Russia
dc.description.affiliationUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil
dc.description.affiliationUniv Antioquia, Dept Microbiol & Parasitol, Fac Med, Grp Inmunodeficiencias Primarias, Medellin, Colombia
dc.description.affiliationTel Aviv Univ, Pediat Dept A, Tel Aviv, Israel
dc.description.affiliationTel Aviv Univ, Affiliated Sackler Fac Med, Jeffrey Modell Fdn Ctr, Sheba Med Ctr,Immunol Serv, Tel Aviv, Israel
dc.description.affiliationMarmara Med Fac, Div Pediat Allergy & Immunol, Istanbul, Turkey
dc.description.affiliationPGIMER, Adv Pediat Ctr, Pediat Allergy & Immunol Unit, Chandigarh, India
dc.description.affiliationRicardo Gutierrez Hosp Ninos, Buenos Aires, DF, Argentina
dc.description.affiliationInst Nacl Pediatria, Clin Immunol & Allergy Unit, Mexico City, DF, Mexico
dc.description.affiliationDmitry Rogachev Fed Res, Dept Clin Immunol, Moscow, Russia
dc.description.affiliationClin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia
dc.description.affiliationUniv Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China
dc.description.affiliationUniv Hong Kong, Shenzhen Hosp, Shenzhen Primary Immunodeficiency Diagnost & Ther, Shenzhen, Peoples R China
dc.description.affiliationNatl Def Med Coll, Dept Pediat, Saitama, Japan
dc.description.affiliationUniv Tunis El Manar, Inst Pasteur Tunis, Dept Immunol, Tunis, Tunisia
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipBill & Melinda Gates Foundation
dc.description.sponsorshipIDBill & Melinda Gates Foundation
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.3389/fimmu.2017.00685]
dc.identifier.citationFrontiers In Immunology. Lausanne, v. 8, p. -, 2017.
dc.identifier.doi10.3389/fimmu.2017.00685
dc.identifier.fileWOS000403113800002.pdf
dc.identifier.issn1664-3224
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/53661
dc.identifier.wosWOS:000403113800002
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Immunology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectpoliovirus eradicationen
dc.subjectimmunodeficiency-associated vaccine-derived poliovirusesen
dc.subjectoral poliovirus vaccineen
dc.subjecthumoral immunodeficiencyen
dc.subjectcombined immunodeficiencyen
dc.subjectprimary immunodeficiencyen
dc.titlePatients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradicationen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000403113800002.pdf
Tamanho:
320.73 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos